Sorafenib and Pleural effusion - a phase IV clinical study of FDA data

Summary:

Pleural effusion is reported as a side effect among people who take Sorafenib (sorafenib), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Afinitor, and have Metastatic renal cell carcinoma.

The phase IV clinical study analyzes which people have Pleural effusion when taking Sorafenib. It is created by eHealthMe based on reports of 3,194 people who have side effects when taking Sorafenib from the FDA, and is updated regularly.

What is Sorafenib?

Sorafenib has active ingredients of sorafenib. eHealthMe is studying from 3,201 Sorafenib users. Check the latest studies of Sorafenib.

What is Pleural effusion?

Pleural effusion (water on the lungs) is found to be associated with 2,221 drugs and 3,149 conditions by eHealthMe. Check the latest studies of Pleural effusion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

3,194 people reported to have side effects when taking Sorafenib.
Among them, 42 people (1.31%) have Pleural effusion.

Among these 42 people:

How long have people been on Sorafenib when they have Pleural effusion? *

What is the gender of people who have Pleural effusion when taking Sorafenib? *

female: 50 %
male: 50 %

What is the age of people who have Pleural effusion when taking Sorafenib? *

What are other drugs people take besides Sorafenib? *

What are other side effects people have besides Pleural effusion? *

Dyspnea (difficult or laboured breathing): 13 people, 30.95%
Malignant Neoplasm Progression (cancer tumour came back): 8 people, 19.05%
Nausea (feeling of having an urge to vomit): 5 people, 11.90%
Anaemia (lack of blood): 5 people, 11.90%
Pneumonia: 5 people, 11.90%
Diarrhea: 5 people, 11.90%
Disease Progression: 5 people, 11.90%
Rashes (redness): 4 people, 9.52%
Fever: 4 people, 9.52%
Nausea And Vomiting: 4 people, 9.52%

What are the existing conditions these people have? *

Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 9 people, 21.43%
Hepatocellular Carcinoma (liver cancer): 7 people, 16.67%
Angiosarcoma (cancer of endothelial-type cells that line vessel walls): 3 people, 7.14%
Thyroid Cancer: 3 people, 7.14%
Medullary Thyroid Cancer (type of thyroid cancer that develops in the parafollicular cells of the thyroid gland): 3 people, 7.14%
Non-Small Cell Lung Cancer Stage Iv: 2 people, 4.76%
Desmoid Tumor: 2 people, 4.76%
Insomnia (sleeplessness): 2 people, 4.76%
Lung Cancer - Non-Small Cell (lung cancer): 2 people, 4.76%
Nausea (feeling of having an urge to vomit): 2 people, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Sorafenib and have Pleural effusion?

- Check whether Pleural effusion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sorafenib:

Sorafenib (3,201 reports)

Pleural effusion treatments and more:

Pleural effusion (84,634 reports)

Browse all side effects of Sorafenib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pleural effusion:

Pleural effusion (2,221 drugs)

Browse all the conditions that are associated with Pleural effusion:

Pleural effusion (3,149 conditions)

Related publications that referenced our studies

Musri FY, Mutlu H, K?vrak Salim D, Karakurt Ery?lmaz M, ?nal B, Tural D, ?enol Co?kun H, "Sorafenib-induced severe urticaria in a patient with hepatocellular cancer", Journal of Oncology Pharmacy Practice, 2016 Jan .
Musri FY, Mutlu H, K?vrak Salim D, Karakurt Ery?lmaz M, ?nal B, Tural D, ?enol Co?kun H, "Sorafenib-induced severe urticaria in a patient with hepatocellular cancer", Journal of Oncology Pharmacy Practice, 2016 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on sorafenib (the active ingredients of Sorafenib) and Sorafenib (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.